246 related articles for article (PubMed ID: 35167695)
21. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.
Shu X; Shao Y; Chen Y; Zeng C; Huang X; Wei R
Front Immunol; 2024; 15():1392956. PubMed ID: 38817600
[TBL] [Abstract][Full Text] [Related]
22. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.
Smith TJ
Nat Rev Endocrinol; 2015 Mar; 11(3):171-81. PubMed ID: 25560705
[TBL] [Abstract][Full Text] [Related]
23. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Smith TJ
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
[TBL] [Abstract][Full Text] [Related]
24. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
[TBL] [Abstract][Full Text] [Related]
25. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
26. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
27. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
28. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
29. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
31. Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.
Wang H; Atkins SJ; Fernando R; Wei RL; Smith TJ
Endocrinology; 2015 Nov; 156(11):4336-44. PubMed ID: 26287404
[TBL] [Abstract][Full Text] [Related]
32. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
33. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
34. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
35. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
Singh G; Taylor B; Michalek S
Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
[TBL] [Abstract][Full Text] [Related]
36. PAPP-A as a Potential Target in Thyroid Eye Disease.
Conover CA; Bale LK; Stan MN
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38752390
[TBL] [Abstract][Full Text] [Related]
37. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
38. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JA
Front Endocrinol (Lausanne); 2016; 7():167. PubMed ID: 28096798
[TBL] [Abstract][Full Text] [Related]
39. A New Era in the Treatment of Thyroid Eye Disease.
Patel A; Yang H; Douglas RS
Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
[TBL] [Abstract][Full Text] [Related]
40. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]